Experience conducting COVID-19 vaccine effectiveness studies in response to the COVID-19 pandemic in Japan and the Philippines: lessons for future epidemics and potential pandemics

Authors

  • Takeshi Arashiro Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom of Great Britain and Northern Ireland; School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan; Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo, Japan; Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan; World Health Organization Regional Office for the Western Pacific, Manila, Philippines https://orcid.org/0000-0002-5215-1500
  • Regina Pascua Berba Hospital Infection Control Unit, Philippine General Hospital, Manila, Philippines
  • Joy Potenciano Calayo Department of Laboratory, San Lazaro Hospital, Manila, Philippines
  • Rontgene Solante Adult Infectious Diseases and Tropical Medicine Unit, San Lazaro Hospital, Manila, Philippines
  • Shuichi Suzuki San Lazaro Hospital-Nagasaki University Collaborative Research Office and Laboratory, San Lazaro Hospital, Manila, Philippines
  • Jinho Shin World Health Organization Regional Office for the Western Pacific, Manila, Philippines
  • Motoi Suzuki Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo, Japan
  • Martin Hibberd Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom of Great Britain and Northern Ireland
  • Koya Ariyoshi School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan
  • Chris Smith Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom of Great Britain and Northern Ireland; School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan

DOI:

https://doi.org/10.5365/wpsar.2025.16.2.1157

Keywords:

SARS-CoV-2, COVID-19, vaccines, vaccine effectiveness, pandemic preparedness, Japan, Philippines

Abstract

Problem: Once COVID-19 vaccines were rolled out, there was a need to monitor real-world vaccine effectiveness to accumulate evidence to inform policy and risk communication. This was especially true in Japan and the Philippines, given historical issues that affected vaccine confidence.

Context: Neither country had public health surveillance that could be enhanced to evaluate vaccine effectiveness or readily available national vaccination databases.

Action: Study groups were established in multiple health-care facilities in each country to assess vaccine effectiveness against both symptomatic infection and severe disease.

Outcome: In Japan, multiple study reports were published in Japanese on the website of the National Institute of Infectious Diseases and presented at the national government’s advisory board. Nationwide media coverage facilitated transparency and increased the confidence of the government and the public in the vaccination programme. In the Philippines, the launch of the study was delayed so as to align the research plan with the interests of various stakeholders and to obtain institutional review board approval. Ultimately, the studies were successfully initiated and completed.

Discussion: There were four main challenges in conducting our studies: finding health-care facilities for data collection; obtaining exposure (vaccination) data; identifying epidemiological biases and confounders; and informing policy and risk communication in a timely manner. Preparedness during inter-emergency/epidemic/pandemic periods to rapidly evaluate relevant interventions such as vaccination is critical and should include the following considerations: (1) the establishment and maintenance of prospective data collection platforms, ideally under public health surveillance (if not, clinical research networks or linked databases); (2) uniform and practical protocols considering biases and confounders; and (3) communication with stakeholders including institutional review boards.

Downloads

Published

04-06-2025

How to Cite

1.
Arashiro T, Berba RP, Calayo JP, Solante R, Suzuki S, Shin J, Suzuki M, Hibberd M, Ariyoshi K, Smith C. Experience conducting COVID-19 vaccine effectiveness studies in response to the COVID-19 pandemic in Japan and the Philippines: lessons for future epidemics and potential pandemics. Western Pac Surveill Response J [Internet]. 2025 Jun. 4 [cited 2026 Mar. 20];16(2). Available from: https://ojs.wpro.who.int/ojs/index.php/wpsar/article/view/1157

Issue

Vol. 16 No. 2 (2025): April – June

Section

Lessons from the Field

License

You are free to:

  • Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.
  • The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Notices:

When the Licensor is an intergovernmental organization, disputes will be resolved by mediation and arbitration unless otherwise agreed.

You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.

No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.

Most read articles by the same author(s)